Patient considerations in the management of gout and role of combination treatment with lesinurad

References

• KhannaDFitzgeraldJDKhannaPP2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care Res (Hoboken)201264101431144623024028
   PubMed Web of Science ®Google Scholar
• RichettePDohertyMPascualE2016 updated EULAR evidence-based recommendations for the management of goutAnn Rheum Dis2017761294227457514
   PubMed Web of Science ®Google Scholar
• QaseemAHarrisRPForcieaMAClinical Guidelines Committee of the American College of PhysiciansManagement of acute and recurrent gout: a clinical practice guideline from the American College of PhysiciansAnn Intern Med20171661586827802508
   PubMed Web of Science ®Google Scholar
• SinghJAStrandVGout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veteransAnn Rheum Dis20086791310131618178692
   PubMed Web of Science ®Google Scholar
• SinghJAChallenges faced by patients in gout treatment: a qualitative studyJ Clin Rheumatol201420317217424662562
   PubMed Web of Science ®Google Scholar
• WilsonLSaseenJJGouty arthritis: a review of acute management and preventionPharmacotherapy201636890692227318031
   PubMed Web of Science ®Google Scholar
• ZhuYPandyaBJChoiHKComorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008Am J Med2012125767968722626509
   PubMed Web of Science ®Google Scholar
• ChoiHKA prescription for lifestyle change in patients with hyperuricemia and goutCurr Opin Rheumatol201022216517220035225
   PubMed Web of Science ®Google Scholar
• ScheepersLEJMvan OnnaMStehouwerCDASinghJAArtsICWBoonenAMedication adherence among patients with gout: a systematic review and meta-analysisSemin Arthritis Rheum201847568970229198878
   PubMed Web of Science ®Google Scholar
• De VeraMAMarcotteGRaiSGaloJSBholeVMedication adherence in gout: a systematic reviewArthritis Care Res (Hoboken)201466101551155924692321
   PubMed Web of Science ®Google Scholar
• BriesacherBAAndradeSEFouayziHChanKAComparison of drug adherence rates among patients with seven different medical conditionsPharmacotherapy200828443744318363527
   PubMed Web of Science ®Google Scholar
• HarroldLRMazorKMVeltenSOckeneISYoodRAPatients and providers view gout differently: a qualitative studyChronic Illn20106426327120675361
   PubMedGoogle Scholar
• Nasser-GhodsiNHarroldLROvercoming adherence issues and other barriers to optimal care in goutCurr Opin Rheumatol201527213413825633242
   PubMed Web of Science ®Google Scholar
• SiveraFAndrésMCarmonaLMultinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiativeAnn Rheum Dis201473232833523868909
   PubMed Web of Science ®Google Scholar
• DalbethNBardinTDohertyMDiscordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)Nat Rev Rheumatol201713956156828794514
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRMacDonaldPALloydELademacherCClinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with goutJ Rheumatol20093661273128219286847
   PubMed Web of Science ®Google Scholar
• SchumacherHRBeckerMALloydEMacDonaldPALademacherCFebuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety studyRheumatology2008482188194
   Web of Science ®Google Scholar
• SundyJSBarafHSBYoodRAEfficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trialsJAMA2011306771172021846852
   PubMed Web of Science ®Google Scholar
• BeckerMABarafHSBYoodRALong-term safety of pegloticase in chronic gout refractory to conventional treatmentAnn Rheum Dis20137291469147423144450
   PubMed Web of Science ®Google Scholar
• ChandratrePRoddyEClarsonLRichardsonJHiderSLMallenCDHealth-related quality of life in gout: a systematic reviewRheumatology (Oxford)201352112031204023934311
   PubMed Web of Science ®Google Scholar
• TatlockSRüdellKPanterCWhat outcomes are important for gout patients? In-depth qualitative research into the gout patient experience to determine optimal endpoints for evaluating therapeutic interventionsPatient2017101657927384670
   PubMedGoogle Scholar
• StrandVKhannaDSIinghJAForsytheAEdwardsNLImproved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trialsJ Rheumatol20123971450145722660805
   PubMed Web of Science ®Google Scholar
• LoebJNThe influence of temperature on the solubility of monosodium urateArthritis Rheum19721521891925027604
   PubMed Web of Science ®Google Scholar
• ChhanaALeeGDalbethNFactors influencing the crystallization of monosodium urate: a systematic literature reviewBMC Musculoskelet Disord201516129626467213
   PubMed Web of Science ®Google Scholar
• GuerraT webpage on the InternetThe Top 200 Drugs of 2017?2017 Available from: http://www.pharmacytimes.com/contributor/tony-guerra-pharmd/2017/03/the-top-200-drugs-of-2017Accessed December 16, 2017
   Google Scholar
• HatoumHKhannaDLinSAkhrasKSShiozawaAKhannaPAchieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostatPostgrad Med20141262657524685969
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRWortmannRLFebuxostat compared with allopurinol in patients with hyperuricemia and goutN Engl J Med2005353232450246116339094
   PubMed Web of Science ®Google Scholar
• ReindersMKHaagsmaCJansenTLA randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with goutAnn Rheum Dis200968689289718633127
   PubMed Web of Science ®Google Scholar
• StampLKO’DonnellJLZhangMUsing allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairmentArthritis Rheum201163241242121279998
   PubMed Web of Science ®Google Scholar
• StampLKChapmanPTBarclayMAllopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension studyAnn Rheum Dis201776122065207028830881
   PubMed Web of Science ®Google Scholar
• Drug Safety and Availability [webpage on the Internet]FDA Drug Safety Communication: FDA to Evaluate Increased Risk of Heart-Related Death and Death from All Causes with the Gout Medicine Febuxostat (Uloric)2017 Available from: https://www.fda.gov/Drugs/DrugSafety/ucm584702.htmAccessed December 16, 2017
   Google Scholar
• WhiteWBChohanSDabholkarAHuntBJacksonRCardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbiditiesAm Heart J20121641142022795277
   PubMed Web of Science ®Google Scholar
• KyddASSethRBuchbinderREdwardsCJBombardierCUricosuric medications for chronic goutKyddASCochrane Database Syst Rev201411CD01045725392987
   PubMed Web of Science ®Google Scholar
• SaagKGFitz-PatrickDKopickoJLesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-Based study)Arthritis Rheumatol201769120321227564409
   PubMed Web of Science ®Google Scholar
• BardinTKeenanRTKhannaPPLesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)Ann Rheum Dis201776581182027821644
   PubMed Web of Science ®Google Scholar
• DalbethNJonesGTerkeltaubRLesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout findings of a phase III clinical trialArthritis Rheumatol20176991903191328597604
   PubMed Web of Science ®Google Scholar
• TauscheAKAltenRDalbethNLesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension studyRheumatology (Oxford)201756122170217829029210
   PubMed Web of Science ®Google Scholar
• Zurampic (lesinurad) [package insert]Wilmington, DEAstraZeneca Pharmaceutical LP2015
   Google Scholar
• Ironwood Pharmaceuticals [webpage on the Internet]Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update2017 Available from: http://investor.ironwoodpharma.com/releasedetail.cfm?ReleaseID=1025239Accessed December 17, 2017
   Google Scholar
• Ironwood Pharmaceuticals [webpage on the Internet]Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update (NASDAQ:IRWD)2017 Available from: http://investor.ironwood-pharma.com/releasedetail.cfm?ReleaseID=1035981Accessed December 17, 2017
   Google Scholar
• Ironwood Pharmaceuticals [webpage on the Internet]Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update2017 Available from: http://investor.ironwoodpharma.com/releasedetail.cfm?ReleaseID=1046754Accessed December 17, 2017
   Google Scholar
• LatourteABardinTClersonPEaH-KFlipoR-MRichettePDyslipidemia, alcohol consumption and obesity are the main factors associated with poor control of urate levels in patients receiving urate-lowering therapyArthritis Care Res (Hoboken) Epub2017822
   Web of Science ®Google Scholar